Related references
Note: Only part of the references are listed.N(6)-adenosine-methyltransferase-14 promotes glioma tumorigenesis by repressing argininosuccinate synthase 1 expression in an m6A-dependent manner
You-Qing Miao et al.
BIOENGINEERED (2022)
A Phase 1 study of ADI-PEG20 (pegargiminase) combined with cisplatin and pemetrexed in ASS1-negative metastatic uveal melanoma
Pui Ying Chan et al.
PIGMENT CELL & MELANOMA RESEARCH (2022)
Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies
Shuyang Yao et al.
BRITISH JOURNAL OF CANCER (2021)
Arginine deprivation as a strategy for cancer therapy: An insight into drug design and drug combination
Yu Zhang et al.
CANCER LETTERS (2021)
A phase II clinical study on the efficacy and predictive biomarker of pegylated recombinant arginase on hepatocellular carcinoma
Stephen L. Chan et al.
INVESTIGATIONAL NEW DRUGS (2021)
Argininosuccinate synthase 1 suppresses tumor progression through activation of PERK/eIF2α/ATF4/CHOP axis in hepatocellular carcinoma
Sanghwa Kim et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)
ASS1 and ASL suppress growth in clear cell renal cell carcinoma via altered nitrogen metabolism
Sanika Khare et al.
CANCER & METABOLISM (2021)
Naturally-occurring spinosyn A and its derivatives function as argininosuccinate synthase activator and tumor inhibitor
Zizheng Zou et al.
NATURE COMMUNICATIONS (2021)
Snail enhances arginine synthesis by inhibiting ubiquitination-mediated degradation of ASS1
Hao Jia et al.
EMBO REPORTS (2021)
Pyrimidine Biosynthetic Enzyme CAD: Its Function, Regulation, and Diagnostic Potential
Guanya Li et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Safety, PK/PD and preliminary anti-tumor activities of pegylated recombinant human arginase 1 (BCT-100) in patients with advanced arginine auxotrophic tumors
Paul N. M. Cheng et al.
INVESTIGATIONAL NEW DRUGS (2021)
Phase 1, pharmacogenomic, dose-expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1-deficient non-squamous non-small cell lung cancer
Peter W. Szlosarek et al.
CANCER MEDICINE (2021)
Arginine Signaling and Cancer Metabolism
Chia-Lin Chen et al.
CANCERS (2021)
The prognostic and therapeutic implications of distinct patterns of argininosuccinate synthase 1 (ASS1) and arginase-2 (ARG2) expression by cancer cells and tumor stroma in non-small-cell lung cancer
Alexandra Giatromanolaki et al.
CANCER & METABOLISM (2021)
Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers
Kwang-Yu Chang et al.
ONCOIMMUNOLOGY (2021)
Arginine deprivation inhibits pancreatic cancer cell migration, invasion and EMT via the down regulation of Snail, Slug, Twist, and MMP1/9
Huan Wang et al.
JOURNAL OF PHYSIOLOGY AND BIOCHEMISTRY (2020)
A non-proliferative role of pyrimidine metabolism in cancer
Aarif Siddiqui et al.
MOLECULAR METABOLISM (2020)
lncRNA 00312 Attenuates Cell Proliferation and Invasion and Promotes Apoptosis in Renal Cell Carcinoma via miR-34a-5p/ASS1 Axis
Jiawei Zeng et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2020)
Modulating pyrimidine ribonucleotide levels for the treatment of cancer
Tanzina Mollick et al.
CANCER & METABOLISM (2020)
METTL14-mediated N6-methyladenosine modification of SOX4 mRNA inhibits tumor metastasis in colorectal cancer
Xiaoxiang Chen et al.
MOLECULAR CANCER (2020)
Targeting purine synthesis in ASS1-expressing tumors enhances the response to immune checkpoint inhibitors
Rom Keshet et al.
NATURE CANCER (2020)
Histone deacetylase inhibition is synthetically lethal with arginine deprivation in pancreatic cancers with low argininosuccinate synthetase 1 expression
Stephanie S. Kim et al.
THERANOSTICS (2020)
Molecular Mechanisms of Nitric Oxide in Cancer Progression, Signal Transduction, and Metabolism
Veena Somasundaram et al.
ANTIOXIDANTS & REDOX SIGNALING (2019)
A Phase I Study of Pegylated Arginine Deiminase ( Pegargiminase), Cisplatin, and Pemetrexed in Argininosuccinate Synthetase 1-Deficient Recurrent High-grade Glioma
Peter E. Hall et al.
CLINICAL CANCER RESEARCH (2019)
Androgen receptor regulates ASS1P3/miR-34a-5p/ASS1 signaling to promote renal cell carcinoma cell growth
Kefeng Wang et al.
CELL DEATH & DISEASE (2019)
MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion
Milind D. Chalishazar et al.
CLINICAL CANCER RESEARCH (2019)
Amino acid metabolism in hematologic malignancies and the era of targeted therapy
Yoko Tabe et al.
BLOOD (2019)
Exploiting Arginine Auxotrophy with Pegylated Arginine Deiminase (ADI-PEG20) to Sensitize Pancreatic Cancer to Radiotherapy via Metabolic Dysregulation
Pankaj K. Singh et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Acid-Induced Downregulation of ASS1 Contributes to the Maintenance of Intracellular pH in Cancer
Alon Silberman et al.
CANCER RESEARCH (2019)
Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma
G. K. Abou-Alfa et al.
ANNALS OF ONCOLOGY (2018)
Metabolomic profiling identifies distinct phenotypes for ASS1 positive and negative GBM
Lina Moren et al.
BMC CANCER (2018)
Rewiring of cisplatin-resistant bladder cancer cells through epigenetic regulation of genes involved in amino acid metabolism
Austin Yeon et al.
THERANOSTICS (2018)
Arginine starvation kills tumor cells through aspartate exhaustion and mitochondrial dysfunction
Chun-Ting Cheng et al.
COMMUNICATIONS BIOLOGY (2018)
Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers
Emma Beddowes et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Arginine Deprivation Inhibits the Warburg Effect and Upregulates Glutamine Anaplerosis and Serine Biosynthesis in ASS1-Deficient Cancers
Jeff Charles Kremer et al.
CELL REPORTS (2017)
Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma A Randomized Clinical Trial
Peter W. Szlosarek et al.
JAMA ONCOLOGY (2017)
A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients
Hui-Jen Tsai et al.
SCIENTIFIC REPORTS (2017)
A Phase 1/1B Trial of ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma
Maeve A. Lowery et al.
CANCER (2017)
Argininosuccinate Synthase 1 is a Metabolic Regulator of Colorectal Cancer Pathogenicity
Leslie A. Bateman et al.
ACS CHEMICAL BIOLOGY (2017)
Argininosuccinate synthetase 1 (ASS1) is a common metabolic marker of chemosensitivity for targeted arginine- and glutamine-starvation therapy
Yan Long et al.
CANCER LETTERS (2017)
The Emerging Hallmarks of Cancer Metabolism
Natalya N. Pavlova et al.
CELL METABOLISM (2016)
A metabolic synthetic lethal strategy with arginine deprivation and chloroquine leads to cell death in ASS1-deficient sarcomas
Gregory R. Bean et al.
CELL DEATH & DISEASE (2016)
Inhibition of the Polyamine Synthesis Pathway Is Synthetically Lethal with Loss of Argininosuccinate Synthase 1
Matthew Locke et al.
CELL REPORTS (2016)
Arginine deprivation using pegylated arginine deiminase has activity against primary acute myeloid leukemia cells in vivo
Farideh Miraki-Moud et al.
BLOOD (2015)
Diversion of aspartate in ASS1-deficient tumours fosters de novo pyrimidine synthesis
Shiran Rabinovich et al.
NATURE (2015)
Prognostic and Therapeutic Impact of Argininosuccinate Synthetase 1 Control in Bladder Cancer as Monitored Longitudinally by PET Imaging
Michael D. Allen et al.
CANCER RESEARCH (2014)
ASS1 as a Novel Tumor Suppressor Gene in Myxofibrosarcomas: Aberrant Loss via Epigenetic DNA Methylation Confers Aggressive Phenotypes, Negative Prognostic Impact, and Therapeutic Relevance
Hsuan-Ying Huang et al.
CLINICAL CANCER RESEARCH (2013)
Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma
Patrick A. Ott et al.
INVESTIGATIONAL NEW DRUGS (2013)
Arginine Deiminase Resistance in Melanoma Cells Is Associated with Metabolic Reprogramming, Glucose Dependence, and Glutamine Addiction
Yan Long et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma
N. Syed et al.
CELL DEATH & DISEASE (2013)
A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients
T-S Yang et al.
BRITISH JOURNAL OF CANCER (2010)
Phase II Study of Pegylated Arginine Deiminase for Nonresectable and Metastatic Hepatocellular Carcinoma
Evan S. Glazer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer
Linda J. Nicholson et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Pegylated arginine deiminase treatment of patients with metastatic melanoma: Results from phase I and II studies
PA Ascierto et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Cellular and physiological effects of arginine
BC Tong et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2004)
Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: Results from phase I/II studies
F Izzo et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Share Paper
